Revolution Medicines (RVMD), Daraxonrasib Phase 3 in Pancreatic Cancer

Revolution Medicines dropped Phase 3 results this morning for daraxonrasib in second-line pancreatic cancer and the data is practice-changing.

Median overall survival came in at 13.2 months versus 6.7 months for chemotherapy. That's a 6.5 month improvement and a 60% reduction in the risk of death. CEO Mark Goldsmith called the results unprecedented, noting that no drug has ever shown an overall survival benefit greater than one year in a Phase 3 pancreatic cancer trial. The drug met all primary and secondary endpoints.

The stock is up roughly 34% on the news.

Why This Matters

Pancreatic cancer has the lowest five-year survival rate of any major cancer at 13%. The standard of care has been exclusively IV chemotherapy for decades. No targeted therapy has ever succeeded in a Phase 3 trial in this disease. That changes today.

Daraxonrasib is a daily oral pill that broadly targets RAS mutations, which drive tumor growth in approximately 90% of pancreatic cancer cases. RAS was considered undruggable for most of the history of modern oncology. Revolution Medicines built a platform around cracking that problem and this data validates it in the most definitive way possible, a Phase 3 overall survival win.

The Details

The trial enrolled patients whose cancer had already progressed on prior treatment, so this is a second-line setting. Patients on daraxonrasib typically lived nearly twice as long as patients on chemotherapy. The safety profile was manageable with no new concerns. Rash is a known class effect and generally treatable.

RevMed plans to seek FDA approval using a Commissioner's National Priority Voucher, which grants a review within months rather than the standard timeline. They also have a Phase 3 trial underway in first-line (newly diagnosed) pancreatic cancer, which would dramatically expand the addressable patient population if successful.

Strategic Value

This is one of the most valuable oncology assets in biotech right now. A validated oral pan-RAS inhibitor with Phase 3 overall survival data doesn't exist anywhere else. RAS mutations aren't limited to pancreatic cancer. They're prevalent across lung, colorectal, and multiple other tumor types. The platform expansion potential is enormous.

At a roughly $22B implied market cap after today's move, RVMD is in large-cap biotech territory. That limits the traditional M&A math since you'd need a $30B+ deal to make the acquisition premium work. But strategic interest from Merck, Roche, AstraZeneca, or Lilly wouldn't be surprising given what this data represents. Merck in particular needs pipeline reinforcement as Keytruda faces biosimilar risk, and a best-in-class RAS inhibitor would fit that strategy well.

That said, RVMD can absolutely win as a standalone. The first-line pancreatic data, multi-tumor expansion, and accelerated regulatory path give them a clear commercial trajectory without needing a buyer.